Excessive Daytime Sleepiness Market Report 2026

Excessive Daytime Sleepiness Market Overview

• Excessive Daytime Sleepiness market size has reached to $5.39 billion in 2025 • Expected to grow to $8.52 billion in 2030 at a compound annual growth rate (CAGR) of 9.6% • Growth Driver: Rising Obstructive Sleep Apnea Prevalence Driving The Market Growth Due To Increasing Obesity And Sleep Disorders • Market Trend: Next-Generation Therapeutics Coupled With Virtual Healthcare Models • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Excessive Daytime Sleepiness Market?

Excessive daytime sleepiness is a medical condition characterized by a persistent inability to stay awake and alert during normal waking hours. It is commonly associated with underlying sleep disorders, neurological conditions, or lifestyle factors that disrupt normal sleep patterns. This condition can significantly impact daily functioning, cognitive performance, and overall quality of life. The main treatment types of excessive daytime sleepiness include pharmacological treatment, behavioral therapy, continuous positive airway pressure therapy, lifestyle modification programs, and combination therapies. Pharmacological treatment refers to the use of medications to reduce sleepiness and improve wakefulness in affected patients. These treatments are applied using diagnosis methods such as polysomnography, multiple sleep latency test, actigraphy, clinical evaluation, and questionnaire based assessments. The types of disorder include narcolepsy, obstructive sleep apnea, Insomnia, circadian rhythm disorders, idiopathic hypersomnia, restless legs syndrome, and other types of disorders. The distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, and the end users are hospitals, sleep clinics, ambulatory surgical centers, and home care settings.

What Is The Excessive Daytime Sleepiness Market Growth Forecast?

The excessive daytime sleepiness market size is expected to see strong growth in the next few years. It will grow to $8.52 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to increasing demand for personalized sleep treatment plans, rising integration of digital therapeutics in sleep care, expansion of remote patient monitoring adoption, growing focus on preventive sleep healthcare, increasing investment in sleep medicine research. Major trends in the forecast period include increasing adoption of wearable sleep monitoring devices, growing use of combination therapy approaches, expansion of home-based sleep disorder management, rising focus on early diagnosis and screening programs, enhanced integration of digital sleep health platforms.

Global Excessive Daytime Sleepiness Market Segmentation

1) By Treatment Type: Pharmacological Treatment; Behavioral Therapy; Continuous Positive Airway Pressure Therapy; Lifestyle Modification Programs; Combination Therapies 2) By Diagnosis Method: Polysomnography; Multiple Sleep Latency Test; Actigraphy; Clinical Evaluation; Questionnaire Based Assessments 3) By Type Of Disorder: Narcolepsy; Obstructive Sleep Apnea; Insomnia; Circadian Rhythm Disorders; Idiopathic Hypersomnia; Restless Legs Syndrome; Other Type Of Disorders 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies 5) By End User: Hospitals; Sleep Clinics; Ambulatory Surgical Centers; Home Care Settings Subsegments: 1) By Pharmacological Treatment: Wake Promoting Medications; Central Nervous System Stimulant Medications; Dopamine Reuptake Inhibitor Medications; Histamine Receptor Modulating Medications 2) By Behavioral Therapy: Cognitive Behavioral Therapy For Sleep; Sleep Hygiene Education Programs; Stimulus Control Therapy; Sleep Restriction Therapy 3) By Continuous Positive Airway Pressure Therapy: Fixed Pressure Airway Therapy; Auto Adjusting Airway Therapy; Bilevel Airway Therapy; Adaptive Pressure Support Therapy 4) By Lifestyle Modification Programs: Sleep Schedule Regulation Programs; Diet And Nutrition Management Programs; Physical Activity And Exercise Programs; Stress Management And Relaxation Programs 5) By Combination Therapies: Medication And Behavioral Therapy Combinations; Airway Therapy And Lifestyle Modification Combinations; Medication And Airway Therapy Combinations; Integrated Multimodal Treatment Approaches

What Is The Driver Of The Excessive Daytime Sleepiness Market?

The rising prevalence of obstructive sleep apnea (OSA) is expected to propel the growth of the excessive daytime sleepiness (EDS) market going forward. Obstructive sleep apnea is a sleep disorder characterized by repeated pauses in breathing during sleep due to blockage of the upper airway, leading to fragmented sleep and reduced sleep quality. The prevalence of obstructive sleep apnea is increasing due to rising obesity rates, which cause excess neck and throat fat that narrows the airway and leads to breathing interruptions during sleep. Excessive daytime sleepiness is a common and debilitating symptom of obstructive sleep apnea and often persists in a significant proportion of patients, driving the need for targeted therapeutic and management solutions. For instance, in August 2026, according to the National Library of Medicine, a US-based medical library, by 2050, approximately 76.6 million adults aged 30–69 in the United States are expected to be affected by obstructive sleep apnea. Therefore, the rising prevalence of obstructive sleep apnea is driving the growth of the excessive daytime sleepiness market. Therefore, the rising prevalence of obstructive sleep apnea is driving the growth of the excessive daytime sleepiness industry.

Key Players In The Global Excessive Daytime Sleepiness Market

Major companies operating in the excessive daytime sleepiness market are Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Cleveland Clinic, EisAI Co. Ltd, Jazz Pharmaceuticals plc., Emory Healthcare Inc., Alkermes plc., Fisher & Paykel Healthcare Corporation Limited, Harmony Biosciences Holdings Inc., Medanta, Axsome Therapeutics Inc., Compumedics Limited, BIOPROJET, Apnimed Inc., Nox Health Inc., Somnogen Canada Inc., Suven Life Sciences Limited, Theranexus, XWPharma, NLS Pharmaceutics AG.

Global Excessive Daytime Sleepiness Market Trends and Insights

Major companies operating in the excessive daytime sleepiness market are focusing on developing innovative solutions, such as central nervous system depressants, to improve wakefulness and enhance quality of life for patients. A central nervous system depressant is a substance that reduces nervous system activity, causing sedation, calmness, or sleep. For instance, in September 2025, Amneal Pharmaceuticals Inc., a US-based pharmaceutical company, received an approval from the FDA for sodium oxybate oral solution, which directly treats excessive daytime sleepiness (EDS) in narcolepsy patients. It enhances treatment continuity by facilitating virtual specialist consultations, remote prescription fulfillment, and improved patient reach in underserved regions, with the purpose of expanding access, improving affordability, and aligning established pharmacotherapy with evolving digital and telehealth-driven care models for excessive daytime sleepiness.

What Are Latest Mergers And Acquisitions In The Excessive Daytime Sleepiness Market?

In October 2025, Alkermes plc, an Ireland based biopharmaceutical company, acquired Avadel Pharmaceuticals plc for an undisclosed amount. With this acquisition, Alkermes aims to accelerate its commercial entry into the sleep medicine market, diversify its product portfolio with the FDA approved LUMRYZ therapy, and enhance its capabilities in rare and central disorders of hypersomnolence. Avadel Pharmaceuticals plc is an Ireland based commercial stage biopharmaceutical company that offers treatments for excessive daytime sleepiness.

Regional Insights

North America was the largest region in the excessive daytime sleepiness market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Excessive Daytime Sleepiness Market?

The excessive daytime sleepiness market consists of revenues earned by entities by providing services such as sleep disorder diagnosis and assessment, sleep monitoring and polysomnography services, patient counseling and behavioral therapy sessions, and treatment planning and management. The market value includes the value of related goods sold by the service provider or included within the service offering. The excessive daytime sleepiness market also includes sales of stimulants, modafinil and armodafinil, sodium oxybate, continuous positive airway pressure (CPAP) devices, wearable sleep monitoring devices, and other supportive medical devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Excessive Daytime Sleepiness Market Report 2026?

The excessive daytime sleepiness market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the excessive daytime sleepiness industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.